INC Research Acquires MDS Pharma Services Phase II-IV operations
Divestiture is viewed as a result of MDS's ongoing strategic review process
MDS has completed the divestiture of its phase II-IV operations to INC Research. Under the terms of the agreement, INC Research has acquired MDS Pharma Services' phase II-IV operations, which includes approximately 800 employees who conduct clinical trials in more than 25 countries.
The company expects to provide additional detail with respect to the divestiture of its phase II-IV operations, together with the financial results for its fiscal third quarter .
The company said that its decision to sell its MDS Pharma Services, which consists of phase II-IV operations and Central Labs, are a result of its ongoing strategic review process.
Stephen DeFalco, President and CEO of MDS, said: The completion of this transaction supports our efforts to advance MDS Pharma Services' top-three leadership position in the delivery of Early Stage services.
Related Insight
Suppliers Directory
InnoCore Technologies BV – Injectable and Implantable Drug Delivery Products and Drug-Eluting Medical Devices
InnoCore is a drug delivery company providing controlled release systems for the pharmaceutical and medical device industry.
Suppliers
Random42 - Medical Animation
Random42 is the world’s premier medical animation company. Over the past 20 years we have created over 150 mechanism-of-action (MoA) animations for the world's leading pharmaceutical and biotechnology companies and won over 50 industry awards.
Suppliers
Burkert Fluid Control Systems - Fluid and Gas Control Systems
From the control room to the downstream processing area and with an eye on utilities services the scope of systems and components from Bürkert Fluid Control Systems and our alliance partner BBS Systems makes one of the most comprehensive partnerships in the pharmaceutical and biotechnology segments available to you today.
Suppliers
Nycomed - Contract Services
Nycomed is a privately owned global mid-sized pharmaceutical company with a differentiated portfolio focused on branded medicines in the areas of gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Map Members
Published by ASEBIO
White Papers
Pessimism and Instability Defining the Clinical Research Workforce
Published by CenterWatch
White Papers
Saturated Steam - Efficient Sterilization
Published by Ellab
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.